Identification

Name
Dihydromorphine
Accession Number
DB01565
Type
Small Molecule
Groups
Experimental, Illicit
Description

A semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]

Structure
Thumb
Synonyms
Not Available
External IDs
IDS-ND-009 / NSC-117865
Categories
UNII
C3S5FRP6JW
CAS number
509-60-4
Weight
Average: 287.3535
Monoisotopic: 287.152143543
Chemical Formula
C17H21NO3
InChI Key
IJVCSMSMFSCRME-KBQPJGBKSA-N
InChI
InChI=1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-triene-10,14-diol
SMILES
[H][[email protected]@]12OC3=C(O)C=CC4=C3[[email protected]@]11CCN(C)[[email protected]]([H])(C4)[[email protected]]1([H])CC[[email protected]@H]2O

Pharmacology

Indication

Dihydromorphine is an opioid analgesic used for moderate to severe pain relief.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
UDelta-type opioid receptor
agonist
Human
UKappa-type opioid receptor
agonist
Human
UE3 ubiquitin-protein ligase TRIM13
agonist
Human
UPro-opiomelanocortin
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Dihydromorphine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydromorphine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Agomelatine.Approved, Investigational
AlaproclateDihydromorphine may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Dihydromorphine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dihydromorphine.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Dihydromorphine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Dihydromorphine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydromorphine.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amiloride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Dihydromorphine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydromorphine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Dihydromorphine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dihydromorphine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydromorphine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dihydromorphine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Dihydromorphine.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydromorphine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dihydromorphine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Azaperone.Investigational, Vet Approved
AzelastineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dihydromorphine.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dihydromorphine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dihydromorphine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dihydromorphine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Dihydromorphine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Benzyl alcohol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydromorphine.Approved, Investigational
BL-1020BL-1020 may increase the hypotensive activities of Dihydromorphine.Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Dihydromorphine.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dihydromorphine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brotizolam.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydromorphine.Approved, Investigational
BuprenorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydromorphine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydromorphine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dihydromorphine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dihydromorphine.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydromorphine.Approved, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Canrenone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydromorphine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Dihydromorphine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dihydromorphine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dihydromorphine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dihydromorphine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydromorphine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydromorphine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Dihydromorphine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Dihydromorphine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dihydromorphine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydromorphine.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydromorphine.Approved, Vet Approved
CitalopramDihydromorphine may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clobazam.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydromorphine.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dihydromorphine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dihydromorphine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydromorphine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydromorphine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dihydromorphine.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydromorphine.Approved
DapoxetineDihydromorphine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydromorphine.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydromorphine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desmopressin.Approved
DesvenlafaxineDihydromorphine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dihydromorphine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydromorphine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Dihydromorphine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dihydromorphine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydromorphine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dihydromorphine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dihydromorphine.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydromorphine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Dihydromorphine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dihydromorphine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydromorphine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydromorphine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dihydromorphine.Experimental, Illicit
DuloxetineDihydromorphine may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydromorphine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dihydromorphine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Efonidipine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Eltanolone.Investigational
EluxadolineDihydromorphine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Dihydromorphine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dihydromorphine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Eplerenone.Approved
EscitalopramDihydromorphine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dihydromorphine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydromorphine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Dihydromorphine.Experimental
EthanolDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydromorphine.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dihydromorphine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dihydromorphine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydromorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydromorphine.Approved
EtoperidoneDihydromorphine may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dihydromorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Dihydromorphine.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dihydromorphine.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydromorphine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydromorphine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dihydromorphine.Approved, Illicit
FluoxetineDihydromorphine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydromorphine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dihydromorphine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydromorphine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydromorphine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydromorphine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Dihydromorphine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dihydromorphine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dihydromorphine.Approved, Illicit, Investigational
GepefrineGepefrine may increase the analgesic activities of Dihydromorphine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dihydromorphine.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dihydromorphine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dihydromorphine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dihydromorphine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydromorphine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dihydromorphine.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dihydromorphine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydromorphine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydromorphine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydromorphine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Dihydromorphine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dihydromorphine.Approved
IbopamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ibopamine.Experimental
IloperidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Imipramine.Approved
IndalpineDihydromorphine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Indapamide.Approved
IndiplonThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Dihydromorphine.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydromorphine.Approved
IproclozideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dihydromorphine.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Isosorbide.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydromorphine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dihydromorphine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydromorphine.Approved, Investigational
LevomilnacipranDihydromorphine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydromorphine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dihydromorphine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Dihydromorphine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydromorphine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydromorphine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydromorphine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dihydromorphine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Dihydromorphine.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydromorphine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dihydromorphine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Melperone.Approved, Investigational
MephedroneMephedrone may increase the analgesic activities of Dihydromorphine.Investigational
MephentermineMephentermine may increase the analgesic activities of Dihydromorphine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydromorphine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydromorphine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dihydromorphine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dihydromorphine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dihydromorphine.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Dihydromorphine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dihydromorphine.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydromorphine.Approved
MethotrimeprazineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dihydromorphine.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Dihydromorphine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Dihydromorphine.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dihydromorphine.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Dihydromorphine.Approved
MeticraneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Dihydromorphine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metolazone.Approved
MetyrosineDihydromorphine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydromorphine.Approved, Illicit
MidomafetamineMidomafetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit, Investigational
MilnacipranDihydromorphine may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Investigational
MirtazapineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Dihydromorphine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydromorphine.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dihydromorphine.Approved
NaltrexoneThe therapeutic efficacy of Dihydromorphine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneDihydromorphine may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nialamide.Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dihydromorphine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dihydromorphine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydromorphine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dihydromorphine.Approved
OpiumThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Opium.Approved, Illicit
OrphenadrineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Dihydromorphine.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydromorphine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Oxethazaine.Approved, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Dihydromorphine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dihydromorphine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydromorphine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydromorphine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydromorphine.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dihydromorphine.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydromorphine.Approved
PamabromThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pamabrom.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydromorphine.Approved
ParaldehydeDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pargyline.Approved
ParoxetineDihydromorphine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydromorphine.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dihydromorphine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydromorphine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dihydromorphine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved
PerazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dihydromorphine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydromorphine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenelzine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Dihydromorphine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydromorphine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Dihydromorphine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydromorphine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydromorphine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydromorphine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleDihydromorphine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dihydromorphine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dihydromorphine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dihydromorphine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dihydromorphine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydromorphine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dihydromorphine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dihydromorphine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydromorphine.Approved, Vet Approved
PropericiazinePropericiazine may increase the hypotensive activities of Dihydromorphine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Dihydromorphine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Dihydromorphine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydromorphine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Dihydromorphine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Dihydromorphine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dihydromorphine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydromorphine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dihydromorphine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ramelteon.Approved, Investigational
RamosetronDihydromorphine may increase the constipating activities of Ramosetron.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydromorphine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydromorphine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydromorphine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydromorphine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Dihydromorphine.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Romifidine.Vet Approved
RopiniroleDihydromorphine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydromorphine.Approved
RotigotineDihydromorphine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dihydromorphine.Approved
SafrazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydromorphine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineDihydromorphine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydromorphine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dihydromorphine.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Dihydromorphine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydromorphine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydromorphine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Sultopride.Experimental
SuvorexantDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydromorphine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrodotoxin.Investigational
ThalidomideDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Theobromine.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydromorphine.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Dihydromorphine.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Dihydromorphine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dihydromorphine.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Dihydromorphine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dihydromorphine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dihydromorphine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiapride.Approved, Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tilidine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dihydromorphine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydromorphine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydromorphine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydromorphine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydromorphine.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydromorphine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dihydromorphine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dihydromorphine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dihydromorphine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydromorphine.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Dihydromorphine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dihydromorphine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dihydromorphine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydromorphine.Approved
UlaritideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Dihydromorphine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dihydromorphine.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydromorphine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dihydromorphine.Approved
VenlafaxineDihydromorphine may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydromorphine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ziconotide.Approved
ZimelidineDihydromorphine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydromorphine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zolazepam.Vet Approved
ZolpidemDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dihydromorphine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dihydromorphine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Herbert Merz, Ingrid Wiedemann, Helmut Ensinger, Klaus Stockhaus, Matthias Grauert, "14-hydroxy-N-(2-methoxyethyl)-7,8-dihydromorphine and -norisomorphine, processes for the preparation thereof and the use thereof as pharmaceutical compositions." U.S. Patent US5240933, issued August 31, 1993.

US5240933
General References
Not Available
External Links
Human Metabolome Database
HMDB60548
KEGG Compound
C11782
PubChem Compound
5359421
PubChem Substance
46506587
ChemSpider
4514282
BindingDB
50452273
ChEBI
4575
ChEMBL
CHEMBL1500
Wikipedia
Dihydromorphine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)157 dec °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility1.82 mg/mLALOGPS
logP1.26ALOGPS
logP1.08ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)10.29ChemAxon
pKa (Strongest Basic)9.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area52.93 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.16 m3·mol-1ChemAxon
Polarizability30.66 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.985
Caco-2 permeable+0.8356
P-glycoprotein substrateSubstrate0.8896
P-glycoprotein inhibitor INon-inhibitor0.8653
P-glycoprotein inhibitor IINon-inhibitor0.9868
Renal organic cation transporterInhibitor0.5516
CYP450 2C9 substrateNon-substrate0.8115
CYP450 2D6 substrateSubstrate0.8647
CYP450 3A4 substrateSubstrate0.7582
CYP450 1A2 substrateNon-inhibitor0.797
CYP450 2C9 inhibitorNon-inhibitor0.9309
CYP450 2D6 inhibitorNon-inhibitor0.617
CYP450 2C19 inhibitorNon-inhibitor0.7678
CYP450 3A4 inhibitorNon-inhibitor0.8793
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9646
Ames testNon AMES toxic0.7901
CarcinogenicityNon-carcinogens0.9598
BiodegradationNot ready biodegradable0.9846
Rat acute toxicity2.8928 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8927
hERG inhibition (predictor II)Non-inhibitor0.8414
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Morphinans
Sub Class
Not Available
Direct Parent
Morphinans
Alternative Parents
Phenanthrenes and derivatives / Tetralins / Coumarans / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Trialkylamines / Secondary alcohols / Cyclic alcohols and derivatives
show 4 more
Substituents
Morphinan / Phenanthrene / Tetralin / Coumaran / Alkyl aryl ether / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Piperidine / Benzenoid / Cyclic alcohol
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
morphinane alkaloid (CHEBI:4575)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13. [PubMed:16777416]
  2. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215]
  3. Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30. [PubMed:15178355]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13. [PubMed:16777416]
  2. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215]
  3. Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30. [PubMed:15178355]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Crooks PA, Kottayil SG, Al-Ghananeem AM, Byrn SR, Butterfield DA: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13. [PubMed:16777416]
  2. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215]
  3. Gilbert AK, Hosztafi S, Mahurter L, Pasternak GW: Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol. 2004 May 25;492(2-3):123-30. [PubMed:15178355]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
E3 ubiquitin ligase involved in the retrotranslocation and turnover of membrane and secretory proteins from the ER through a set of processes named ER-associated degradation (ERAD). This process ac...
Gene Name
TRIM13
Uniprot ID
O60858
Uniprot Name
E3 ubiquitin-protein ligase TRIM13
Molecular Weight
46987.08 Da
References
  1. Liebmann C, Schnittler M, Hartrodt B, Born I, Neubert K: Structure-activity studies of novel casomorphin analogues: binding profiles towards mu 1-, mu 2- and delta -opioid receptors. Pharmazie. 1991 May;46(5):345-8. [PubMed:1654566]
  2. Maneckjee R, Archer S, Zukin RS: Characterization of a polyclonal antibody to the mu opioid receptor. J Neuroimmunol. 1988 Feb;17(3):199-208. [PubMed:2828423]
  3. Ishizuka Y, Oka T: Relation of diltiazem binding sites to opioid receptor subtypes in the guinea-pig brain. Tokai J Exp Clin Med. 1987 Mar;12(1):11-7. [PubMed:2835832]
  4. Koman A, Kolb VM, Terenius L: A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. Pharm Res. 1987 Apr;4(2):147-9. [PubMed:2855368]
  5. Ho CL, Hammonds RG Jr, Li CH: Opiate receptor binding profile in the rabbit cerebellum and brain membranes. Biochem Pharmacol. 1985 Apr 1;34(7):925-31. [PubMed:2985086]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Type 4 melanocortin receptor binding
Specific Function
ACTH stimulates the adrenal glands to release cortisol.MSH (melanocyte-stimulating hormone) increases the pigmentation of skin by increasing melanin production in melanocytes.Beta-endorphin and Met...
Gene Name
POMC
Uniprot ID
P01189
Uniprot Name
Pro-opiomelanocortin
Molecular Weight
29423.72 Da
References
  1. Somoza E: Influence of neuroleptics on the binding of met-enkephalin, morphine and dihydromorphine to synaptosome-enriched fractions of rat brain. Neuropharmacology. 1978 Aug;17(8):577-81. [PubMed:29252]
  2. Johnson N, Houghten R, Pasternak GW: Binding of 3H-beta-endorphin in rat brain. Life Sci. 1982 Sep 20-27;31(12-13):1381-4. [PubMed:6292632]

Drug created on July 31, 2007 07:10 / Updated on November 09, 2017 03:01